Study to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRD

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1/PHASE2

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-03-31

Study Completion Date

2076-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the safety and efficacy of the GGTA1 KO Thymokidney in patients with end-stage renal disease (ESRD) who are either not eligible for conventional allogeneic kidney transplantation (Group 1) or are on an Organ Procurement and Transplantation Network (OPTN) kidney transplant waitlist, but are more likely to die or go untransplanted within 5 years than receive a kidney transplant (Group 2).

The study consists of xenotransplantation followed by a 24-week Post-transplant Follow-up Period (Part A) to evaluate the efficacy and safety objectives followed by a Long-term Follow-up Period (Part B) to evaluate participant survival, GGTA1 KO Thymokidney survival, and screening for zoonotic infections. Part B will continue for the lifetime of the participant or for 52 weeks following nephrectomy, if required.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With ESRD

NCT06878560

ESRD (End-Stage Renal Disease) Kidney Transplantation Xenotransplantation

RECRUITING PHASE1/PHASE2

GEnomic Medicine in Kidney Transplantation Study

NCT06365411

Transplant Complication Kidney Transplant Rejection

NOT_YET_RECRUITING

Staged Kidney Transplantation During Combined Heart/Kidney Transplantation

NCT06877169

Heart Failure Chronic Kidney Disease End-stage Kidney Disease

RECRUITING NA

Estimating Glomerular Filtration Rate in Kidney Transplant Recipients

NCT05229939

Kidney Transplantation Glomerular Filtration Rate

COMPLETED

Studies of Kidney Transplant Outcome

NCT01277770

Transplant Recipient (Kidney) Steroid-Free Maintenance Immunosuppression Post-Transplant Infections +1 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a Phase 1/2/3, multicenter, open-label, safety and efficacy study of the GGTA1 KO Thymokidney in patients with ESRD. The study will be comprised of the following:

* A Screening Period up to 52 weeks.
* Part A consists of the GGTA1 KO Thymokidney transplantation followed by a 24-week Post-transplant Follow-up Period, including the evaluation of all study endpoints and safety assessments.
* Part B is a Long-term Follow-up Period that extends for the lifetime of participants who received the GGTA1 KO Thymokidney or for 52 weeks following nephrectomy, if required, including but not limited to documentation of participant survival, GGTA1 KO Thymokidney survival, and screening for zoonotic infections.

There will be 2 groups of participants enrolled in the study. Group 1 will be participants deemed ineligible for conventional allogeneic kidney transplantation due to medical reason(s). Group 2 will be participants on an OPTN kidney transplant waitlist but who are more likely to die or go untransplanted within 5 years than receive a kidney transplant.

For the purpose of the primary analysis, the end of the study is defined as the date of the final visit of the final participant in Part A of the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

ESRD (End-Stage Renal Disease) Kidney Transplantation Xenotransplantation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

This single group study will enroll participants simultaneously from either of 2 patient populations: (1) participants that are ineligible for conventional allogeneic kidney transplantation due to medical reason(s) or (2) participants on an OPTN kidney transplant waitlist that are more likely to die or go untransplanted within 5 years than receive a kidney transplant.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

GGTA1 KO Thymokidney

Participants will receive GGTA1 KO Thymokidney

Group Type EXPERIMENTAL

GGTA1 KO Thymokidney

Intervention Type BIOLOGICAL

Porcine kidney containing an intentional genomic alteration and thymic tissue autograft for xenotransplantation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GGTA1 KO Thymokidney

Porcine kidney containing an intentional genomic alteration and thymic tissue autograft for xenotransplantation

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Provide voluntarily informed consent to participate in the study and for lifetime follow-up.
2. Have a diagnosis of ESRD at the time of informed consent.
3. Hemodialysis dependent for a minimum of 6 months and has a functioning arterial-venous fistula/graft or permanent catheter at the time of informed consent.
4. 50 to 70 years of age at the time of informed consent, or 40 to \<50 years of age with a calculated panel reactive antibody (cPRA) of ≥99.9%.
5. Evidence of thymic involution on chest computed tomography (CT) scan with a thymic region of interest score of ≤1.
6. Live within 3 hours travel time of the xenotransplant center.
7. Female participants must be postmenopausal or permanently sterilized (eg, hysterectomy, bilateral oophorectomy, or bilateral salpingectomy). Male participants must agree to the use of a highly effective method of birth control, if the possibility of conception exists.
8. Negative xeno-crossmatch at Screening and pre-transplant.
9. Estimated Post Transplant Survival Calculator score \>20%.(https://optn.transplant.hrsa.gov/data/allocation-calculators/epts-calculator/).
10. Body mass index ≤35 kg/m2.
11. Have completed or have initiated and plan to complete (meningococcal A, C, W, Y and meningococcal B vaccine series only) Centers for Disease Control and Prevention-recommended courses of age- and risk-factor-appropriate vaccinations.
12. Seropositive (immunoglobulin G) for cytomegalovirus and Epstein-Barr virus.

1\. Ineligible for conventional allogeneic kidney transplantation due to medical reason(s) for any of the following:

1. Ineligible for a living donor transplant.
2. Ineligible for an OPTN kidney transplant waitlist (reason for ineligibility will be collected).
3. Delisted from OPTN kidney transplant waitlist (reason for delisting will be collected).

1. On an OPTN kidney transplant waitlist (active or inactive status).
2. No approved living kidney donors.
3. More likely to die or go untransplanted within 5 years than receive a kidney transplant as measured by the Kidney Transplant Decision Aid at the time of informed consent (select United States for "Choose your state" field and National average for "Choose your transplant program" field; https://www.srtr.org/tools/kidney-transplant-decision-aid/).

Exclusion Criteria

1. Need for multiple organ transplants.
2. Severe medical co-morbidities including, but not limited to:

1. Chronic liver disease.
2. Advanced cardiovascular disease.
3. Severe peripheral vascular disease that limits technical ability to transplant the GGTA1 KO Thymokidney.
4. Severe neurologic diseases or conditions that would preclude meaningful recovery or informed consent.
5. Oral steroid-dependent airway disorder or chronic pulmonary disease or requires chronic, intermittent, or continuous supplemental oxygen.
6. Pulmonary hypertension.
7. Uncontrolled diabetes or sequelae of diabetes mellitus including severe non-proliferative diabetic retinopathy.
8. Severe neurogenic bladder that requires intermittent catheterization.
3. ESRD due to hereditary or structural kidney disease.
4. Active or recently treated malignancy at the time of informed consent.
5. Non-renal cause of hematological disorders associated with anemia (eg, thalassemia and sickle disease).
6. Cannot discontinue chronic anticoagulation therapy (low-dose daily aspirin is permissible).
7. History of major psychiatric disorders with psychiatric hospitalization and/or suicidal ideation within 5 years of informed consent.
8. Being treated for active tuberculosis (TB), have received prophylaxis for positive FDA-approved interferon-gamma release assay, or test positive for TB by FDA-approved interferon-gamma release assay test during Screening.
9. Nucleic acid test (NAT) positive for hepatitis B virus and/or hepatitis C virus, hepatitis B surface antibody (anti-HBs) titer \<10 mIU/mL unless the participant is determined to be a nonresponder to hepatitis B vaccination (a nonresponder is defined as having an anti-HB titer \<10 mIU/mL after having completed both the standard vaccine series and a fourth booster dose and/or second standard vaccine series), and/or positive for human immunodeficiency virus (HIV; HIV-1 and HIV-2 antibody and/or NAT).
10. Not able to independently perform activities of daily life.
11. Have a history of medical noncompliance that may preclude adherence to the demands and requirements of xenotransplantation (eg, history of substance use disorder \[SUD\] within 1 year of informed consent, lack of social support, untreated psychological conditions).

Minimum Eligible Age

40 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No